Nanjing Well Pharmaceutical Group Co.,Ltd.

SHSE:603351 Stock Report

Market Cap: CN¥3.3b

Nanjing Well Pharmaceutical GroupLtd Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Nanjing Well Pharmaceutical GroupLtd.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Chemicals earnings growth38.1%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Nanjing Well Pharmaceutical GroupLtd's (SHSE:603351) Earnings Are Of Questionable Quality

Aug 26
Nanjing Well Pharmaceutical GroupLtd's (SHSE:603351) Earnings Are Of Questionable Quality

Nanjing Well Pharmaceutical GroupLtd's (SHSE:603351) Upcoming Dividend Will Be Larger Than Last Year's

Jun 07
Nanjing Well Pharmaceutical GroupLtd's (SHSE:603351) Upcoming Dividend Will Be Larger Than Last Year's

Little Excitement Around Nanjing Well Pharmaceutical Group Co.,Ltd.'s (SHSE:603351) Earnings

Jun 06
Little Excitement Around Nanjing Well Pharmaceutical Group Co.,Ltd.'s (SHSE:603351) Earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Nanjing Well Pharmaceutical GroupLtd has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SHSE:603351 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/20241,328147162226N/A
6/30/20241,321138131186N/A
3/31/20241,239120107162N/A
12/31/20231,15611247120N/A
9/30/20231,0899520124N/A
6/30/20231,04688-94111N/A
3/31/20231,06794-14188N/A
12/31/20221,11195-125109N/A
9/30/20221,12996-112107N/A
6/30/20221,146106-9854N/A
3/31/20221,105103-13624N/A
12/31/20211,042101-247-12N/A
9/30/2021989109-343-48N/A
6/30/202188999-354-16N/A
3/31/202180894-30046N/A
12/31/2020736100-18993N/A
9/30/202073293-12199N/A
6/30/2020775109-29126N/A
3/31/2020823122-45116N/A
12/31/20198811289130N/A
9/30/2019862138-1101N/A
6/30/2019832127-1980N/A
3/31/201982212344103N/A
12/31/2018801112-1364N/A
9/30/2018779109-480N/A
6/30/2018771108N/A73N/A
3/31/2018720104N/A47N/A
12/31/2017694107N/A71N/A
12/31/201655885N/A128N/A
12/31/201549961N/A81N/A
12/31/201452845N/A75N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 603351's forecast earnings growth is above the savings rate (2.9%).

Earnings vs Market: Insufficient data to determine if 603351's earnings are forecast to grow faster than the CN market

High Growth Earnings: Insufficient data to determine if 603351's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 603351's revenue is forecast to grow faster than the CN market.

High Growth Revenue: Insufficient data to determine if 603351's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 603351's Return on Equity is forecast to be high in 3 years time


Discover growth companies